Working... Menu

The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03526705
Recruitment Status : Not yet recruiting
First Posted : May 16, 2018
Last Update Posted : May 16, 2018
Information provided by (Responsible Party):
Dina Saadi, Cairo University

Brief Summary:

Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several cytokines have been found to be involved in the complex pathogenesis of this disease. Il- 36 is one of the cytokines sharing in psoriasis pathogenesis, as its levels are elevated in psoriatic plaques. NB-UVB is one of the important treatment modalities for psoriasis.

The aim of this study is to detect the effect of NB-UVB on the lesional levels of IL-36 in psoriasis.

Condition or disease Intervention/treatment
Psoriasis Device: NB-UVB

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis Lesional Skin
Estimated Study Start Date : May 15, 2018
Estimated Primary Completion Date : November 15, 2018
Estimated Study Completion Date : December 15, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Intervention Details:
  • Device: NB-UVB

Primary Outcome Measures :
  1. effect of NB-UVB on Il-36 levels in psoriasis [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Egyptian males and females with psoriasis

Inclusion Criteria:

  • Patients with psoriasis vulgaris of both sexes
  • Age between 18 and 60 years old.

Exclusion Criteria:

  • Pregnant females
  • Patients receiving systemic treatment or topical treatment for psoriasis within the past two months.
  • Patients having other dermatological diseases.

Layout table for additonal information
Responsible Party: Dina Saadi, Lecturer, Cairo University Identifier: NCT03526705     History of Changes
Other Study ID Numbers: Kapu1
First Posted: May 16, 2018    Key Record Dates
Last Update Posted: May 16, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases